Retatrutide — 20 mg | Lab Select

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed as a triple agonist at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. The peptide incorporates a C20 fatty diacid moiety via a γGlu-γGlu linker enabling reversible albumin binding and an extended pharmacokinetic profile compatible with once-weekly dosing. Retatrutide is investigated as a unimolecular agonist that engages three complementary incretin and glucagon pathways simultaneously, with research interest in body composition, hepatic lipid metabolism, glycemic endpoints, and energy expenditure in obesity and metabolic disease models. It represents one of the most advanced multi-incretin research compounds currently in development.

Benefits (Research Focus)

• Triple receptor agonism — studied for simultaneous activation of GLP-1, GIP, and glucagon receptors

• Body composition research — investigated for fat-mass and lean-mass partitioning in DIO rodent models

• Glycemic endpoints — examined for fasting glucose and HbA1c parameters in T2D research models

• Energy expenditure — explored for glucagon-mediated thermogenic effects unique among incretin analogs

• Long-acting profile — C20 fatty diacid albumin-binding chemistry for extended half-life research

What Researchers Look At

• Receptor binding affinity and selectivity across GLP-1R / GIPR / GCGR

• cAMP activation curves in cell lines expressing each receptor subtype

• Food intake, body weight, and adipose-tissue change in DIO rodent models

• Hepatic steatosis, ALT/AST, and liver fat fraction endpoints

• Comparative pharmacology versus semaglutide, tirzepatide, and other incretin analogs

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 20 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Retatrutide

• Synonyms: LY3437943; LY-3437943; GLP3 (informal)

• Class: Triple GLP-1 / GIP / glucagon receptor agonist; long-acting incretin analog (39 amino acids)

• Modification: Lipidated with C20 fatty diacid via γGlu-γGlu linker on Lys residue; aminoisobutyric acid (Aib) substitutions for DPP-IV resistance

• Formula / M.W.: C₂₂₁H₃₄₃N₅₃O₆₈, ~4731.30 g/mol

• CAS: 2381089-83-2

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Retatrutide Batch COA — September 18, 2025

• Retatrutide VPeptide Canada — January 16, 2026

• Retatrutide VPeptide Canada — March 13, 2026

• Retatrutide VPeptide Canada — June 3, 2026

• Retatrutide VPeptide Canada — June 10, 2026

• Retatrutide VPeptide Canada — July 21, 2026